SMITHS Group, the global technology company, announced today that its Medical division has received 510(k) clearance from the US Food and Drug Administration (FDA) for a new portable medication delivery system that will make pain management simpler and safer for patients and clinicians.
Smiths Medical’s CADD®-Solis Ambulatory Infusion System is a clinically and technologically advanced portable pain management system that administers pain relief medications, including narcotics, to post-surgery, trauma, cancer and labour patients. The system was developed in cooperation with both expert clinicians and the Human Factors Engineering team at the University Health Network in Toronto.
The CADD®-Solis system boasts innovative safety software which allows hospitals to input their own standardised pain management protocols for their patients, to help clinicians deliver the correct dosages of medication and keep patients safe. By allowing clinicians to only select the standard protocol information that has been pre-determined by hospital administrators, the risk of pump programming errors will be greatly reduced.
Srini Seshadri, Group Managing Director of Smiths Medical, said: “We are very excited about this new system, which is an example of our focus on delivering leading edge technology for high growth markets such as ambulatory infusion. We continually strive to help our customers improve outcomes for their patients.”
He added: “The CADD®-Solis system’s flexible platform will support the fast evolving IT and clinical needs for both the hospital and home.”
The CADD®-Solis ambulatory infusion system is backed by Smiths Medical’s reputation as a leading provider of medication delivery and patient safety products worldwide, with more than 300,000 infusion pumps in use in hospitals and alternate sites of care worldwide.